We scan new podcasts and send you the top 5 insights daily.
Bispecific antibodies targeting VEGF alongside PD-1 or PD-L1 combined with taxanes achieved 70% to 80% response rates in triple-negative breast cancer. Notably, these combinations demonstrated robust efficacy in PD-L1-negative patients, suggesting bispecific construct synergy overcomes VEGF-driven immunosuppression.
The bispecific antibody Ivanesimab binds to the VEGF dimer, creating a "daisy chain" of antibody-VEGF complexes. This multimerization concentrates the drug in the tumor microenvironment, where VEGF is high, and enhances its ability to bind and block PD-1 more effectively than single-molecule approaches.
The rationale for combining ADCs with checkpoint inhibitors extends beyond additive effects. Preclinical data shows ADCs can increase T-cell infiltration into the tumor, potentially turning immunologically 'cold' tumors 'hot.' This offers a promising synergistic strategy, especially for PD-L1 negative patients who typically don't respond to immunotherapy alone.
Beyond simply blocking the PD-1/PD-L1 pathway, these bispecifics may form a macromolecular structure with VEGF and PD-L1 in the tumor microenvironment. This structure can cause the cancer cell to internalize the PD-L1 protein, effectively removing it as a target and creating a dual blockade.
The Begonia trial showed an ~80% response rate by combining an ADC (Dato-DXD) with immunotherapy (Durvalumab) in first-line metastatic TNBC patients, 87% of whom were PD-L1 negative. This suggests ADCs, through immunogenic cell death, may create an immune-responsive environment, expanding IO benefit beyond the traditional biomarker.
Unlike existing standards that often require PD-L1 positivity for immunotherapy benefit, the Zanidatamab/Tisilzumab combination showed efficacy irrespective of PD-L1 status. This significantly expands first-line immunotherapy-based options to the minority of HER2+ patients who are PD-L1 negative and currently have fewer effective treatments.
Bevacizumab is conventionally avoided in squamous non-small cell lung cancer due to fatal hemoptysis risks. Ivonescimab, a bispecific antibody targeting PD-1 and VEGF, relies on cooperative binding: VEGF enhances its PD-1 binding and PD-1 enhances VEGF binding. This concentrates VEGF and checkpoint blockade directly at the tumor microenvironment while sparing non-target tissues, producing statistically significant progression-free and overall survival gains in squamous disease without typical anti-VEGF vascular fatalities.
Bispecific antibodies, which target two antigens like PD-1 and VEGF simultaneously, are viewed as the next major upgrade to standard immunotherapy. Their 'cooperative binding' mechanism is expected to improve efficacy and safety, and early trial data suggest they could replace decade-old checkpoint inhibitors like pembrolizumab as the new standard of care.
Unlike bevacizumab's long 20-day half-life and associated bleeding risks that excluded squamous cell carcinoma patients, new bispecifics have a ~6-day half-life. This results in a similar but less severe toxicity profile, broadening their clinical application to a wider patient population.
The bispecific antibody Pumitamig demonstrated identical overall response rates in both PD-L1 positive and negative triple-negative breast cancer patients. This is significant as it provides a potential immunotherapy option for the two-thirds of patients who are PD-L1 negative and currently ineligible for such treatments.
The next wave in NSCLC immunotherapy involves bispecific antibodies, which are single molecules that simultaneously block both the PD-1/PD-L1 and VEGF pathways. Agents like Ivanesimab are showing superior progression-free survival compared to standard checkpoint inhibitors, establishing this dual-target approach as a leading area of development.